Tissue targeted antigenic activation of the immune response to treat cancers
US9320787B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | May 14, 2013 |
| Grant date | Apr 26, 2016 |
| Priority date | — |
| Expiry date | Jan 1, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides in part methods for treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The compositions may for example include killed or attenuated microbial pathogens, such as whole killed bacterial cells, and may be administered at sites distant from the cancer, for example the skin. In selected embodiments, the invention provides methods for treating a cancer situated in the colon, using formulations of E. coli cells. The administration of the immunogenic compositions may be repeated relatively frequently over a relatively long period of time. In embodiments for intradermal or subcutaneous injection, dosages may be adjusted so that injections reproduce a consistent, visible, inflammatory immune reaction at the site of administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.